

Rutger H Koornstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5003611/publications.pdf>

Version: 2024-02-01

21
papers

2,117
citations

759233

12
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

3768
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	3.7	5
2	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>OncolImmunology</i> , 2020, 9, 1738814.	4.6	13
3	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
4	Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019, 11, 1007.	3.7	22
5	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 127-134.	1.4	56
6	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952.	1.5	24
7	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	2.4	7
8	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. <i>Journal of Immunotherapy</i> , 2019, 42, 208-214.	2.4	12
9	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940.	3.7	29
10	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. <i>Targeted Oncology</i> , 2018, 13, 363-370.	3.6	4
11	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441
12	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	1.4	11
13	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	1.4	11
14	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332.	1.2	8
15	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165.	2.8	77
16	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. <i>Journal of Translational Medicine</i> , 2016, 14, 88.	4.4	10
17	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>OncolImmunology</i> , 2016, 5, e1201625.	4.6	21
18	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	7.0	211

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant tamoxifen synchronizes ER β binding and gene expression profiles related to outcome and proliferation. <i>Oncotarget</i> , 2016, 7, 33901-33918.	1.8	13
20	Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature. <i>European Journal of Cancer</i> , 2014, 50, 1045-1054.	2.8	13
21	Management of fatigue in patients with cancer – A practical overview. <i>Cancer Treatment Reviews</i> , 2014, 40, 791-799.	7.7	87